• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Rheumatology >Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis
【24h】

Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis

机译：托珠单抗是RA和系统性发作的幼年特发性关节炎的良好治疗选择吗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interleukin (IL)-6 is a pleiotropic cytokine that has a major role in inflammatory diseases. The results of two recently published clinical trials that used different study designs demonstrated that tocilizumab, a humanized monoclonal antibody that targets the binding of IL-6 to its receptor, improved the clinical and biological signs of disease activity in both rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis. Adverse events included a higher risk of infections, transient elevation of liver aminotransferases, higher cholesterol levels, and a few allergic reactions. Future studies should investigate the long-term efficacy (clinical and structural) and safety of tocilizumab, including its effect on lipid levels.
机译：白介素（IL）-6是一种多效性细胞因子，在炎症性疾病中起主要作用。两项最近发表的使用不同研究设计的临床试验的结果表明，针对IL-6与其受体结合的人源化单克隆抗体tocilizumab改善了类风湿关节炎和全身性发作的疾病活动的临床和生物学迹象。幼年特发性关节炎。不良事件包括较高的感染风险，肝氨基转移酶的短暂升高，较高的胆固醇水平和一些过敏反应。未来的研究应研究托珠单抗的长期疗效（临床和结构）和安全性，包括其对血脂水平的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号